In the Media

CEO of Osmol Therapeutics Leads Virtual Charge to Develop Ground-Breaking Treatment for Prevent Chemo Side-Effects

Bob Linke, CEO of Osmol, was interviewed for the CEO Leadership Series sponsored by Ashton-Tweed, a life sciences executive search firm Mr. Linke discusses OSM-0205, the company’s ground-breaking CIPN treatment and managing a virtual team during the COVID-19 pandemic.